ResearcherSun Yat-sen UniversityActive in the last 2 years

Xiaoding Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9785-6731; OpenAlex author ID A5087273879. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jconrel.2025.113588 ↗
Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapy. Last author DOI 10.1016/j.biomaterials.2021.121264 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qian Shen · 2 shared papers, 2022–2025 · strength 0.41
- Paper Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic … DOI 10.1016/j.jconrel.2025.113588 ↗
- Paper Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pa… DOI 10.1016/j.biomaterials.2021.121264 ↗
Jinjin Chen · 1 shared paper, 2025 · strength 0.22
- Paper Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic … DOI 10.1016/j.jconrel.2025.113588 ↗
Zixi Zhang · 1 shared paper, 2025 · strength 0.22
- Paper Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic … DOI 10.1016/j.jconrel.2025.113588 ↗
Shuwen Cao · 1 shared paper, 2022 · strength 0.19
- Paper Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pa… DOI 10.1016/j.biomaterials.2021.121264 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.